[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fever-of-unknown-origin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fever-of-unknown-origin":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100634120","phase-2-the-investigators-will-evaluate-the-diagnostic-performance-of-18f-alf-fapi-74-petct-in-inflammatory-disorders-and-compare-it-with-the-current-gold-standard-for-inflammation-fdg-petct-in-three-patient-cohort-patients-presenting-with-fever-of-unknown-origin-igg4-rd-and-axspa-100634120",false,"NCT07535554","The Investigators Will Evaluate the Diagnostic Performance of [18F]-AlF-FAPI-74 PET\u002FCT in Inflammatory Disorders and Compare it With the Current Gold Standard for Inflammation, FDG PET\u002FCT, in Three Patient Cohort: Patients Presenting With Fever of Unknown Origin, IgG4-RD and AxSpA.","Prospective Diagnostic Performance of PET\u002FCT Using the Novel Fibroblast Imaging Tracer [18F]-AlF-FAPI-74 Versus Standard of Care [18F]-FDG in Inflammatory Disorders","Inclusion Criteria FUO:\n\n* An illness of more than 3 weeks' duration,\n* Temperature exceeding 38.3°C on \\> 3 occasions, or elevated inflammatory markers on \\> 3 occasions\n* Diagnosis uncertain despite appropriate first-line investigations.\n\nInclusion criteria IgG4-RD:\n\n* High clinical suspicion of IgG4-RD by an experienced clinician of Internal Medicine, based on anamnesis, physical examination, first-line investigations and blood tests.\n* Patients with a new diagnosis of IgG4-RD on histopathology and need for further assessment of disease extent with PET\u002FCT,\n* Relapse of diagnosed IgG4-RD on histopathology according to an experienced clinician of Internal Medicine\n\nInclusion criteria AxSpA:\n\n* High clinical suspicion of axial spondyloarthropahy according to an experienced rheumatology (based on inflammary back pain \\> 3 months, insidious onset, morning stifness, improvement with exercise and worsening in rest, pain worse at night, age at onset \\\u003C45 years of age, imaging findings).\n* Patient has persisting inflammatory back pain after 2 different types of NSAID's (tried for over 2-4 weeks), and is therefore eligible for biological DMARDS therapy.\n\nExclusion Criteria:\n\n* Participant is mentally or legally incapacitated, doesn't understand the study design or is not willing or capable to undergo all study-specific procedures.\n* Any disorder or condition, which in the Investigator's opinion might jeopardise the participant's safety or compliance with the protocol.\n* Any prior or concomitant treatment(s) that might jeopardise the participant's safety or that would compromise the integrity of the Trial.\n* Female who is pregnant (urinary hCG test will be performed in every WOCBP), breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive (with a relatively high Pearl Index: natural methods, minipill outside postpartum period, spermicides or condoms in monotherapy or no usage of contraception when sexually active are not accepted).\n* Participation in an interventional Trial with an investigational medicinal product (IMP) or device when the trial designs are not considered compatible by the study team.\n* Participation in a clinical scientific study in the last 12 months with a radiation exposure caused by the experimental procedures greater than 1 mSv.\n* Participant has a known hypersensitivity to \\[18F\\]AlF-FAPI-74 or the used excipients.\n* Active treatment has already commenced","ALL","18 Years",{"count":19,"type":20},140,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","The aim of the study to evaluate the performance of new \\[18F\\]-AlF-FAPI-74 PET\u002FCT in three inflammatory disorders (fever of unknown origin, IgG4-related disease and axial spondyloarthritis) and compare with the current stand-of-care \\[18F\\]-FDG PET\u002FCT",[27,28,29,30],"Fever of Unknown Origin","IgG4 Related Disease","Axial Spondylarthritis (axSpA)","Inflammation of Unknown Origin","RECRUITING","2026-04-14",{"date":34,"type":35},"2026-04-17","ACTUAL",{"date":37,"type":35},"2025-09-17",{"date":39,"type":20},"2030-03-31",{"name":41,"class":42},"Universitaire Ziekenhuizen KU Leuven","OTHER"]